Karuna Therapeutics, Inc. (KRTX)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD

Add to watchlist

Visitors trend2W10W9M

121.61-2.90 (-2.33%)

At close: 4:00PM EST

Full screen

Trade prices are not sourced from all markets

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Bearishpattern detected

MACD

View all chart patterns

Performance Outlook

Previous Close	124.51
Open	124.12
Bid	0.00 x 1000
Ask	145.00 x 1000
Day's Range	120.05 - 126.64
52 Week Range	52.62 - 146.97
Volume	430,072
Avg. Volume	187,162

Market Cap	3.286B
Beta (5Y Monthly)	N/A
PE Ratio (TTM)	N/A
EPS (TTM)	-1.90
Earnings Date	May 05, 2021 - May 10, 2021
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	159.83

Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.

Fair Value

XX.XX

Overvalued

Research that delivers an independent perspective, consistent methodology and actionable insight

Related Research

All

News

Press Releases

Research Reports

Business Wire
Karuna Therapeutics Announces Pricing of Public Offering of Common Stock
Karuna Therapeutics, Inc. (NASDAQ: KRTX) ("Karuna"), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced the pricing of an underwritten public offering of 2,083,334 shares of its common stock at a public offering price of $120.00 per share. The gross proceeds to Karuna from the offering, before deducting the underwriting discounts and commissions and other estimated offering expenses, are expected to be approximately $250.0 million. In addition, Karuna has granted the underwriters a 30-day option to purchase up to an additional 312,500 shares of common stock. The offering is expected to close on or about March 4, 2021, subject to customary closing conditions. All the shares in the proposed offering are to be sold by Karuna.
- Orchid Island Capital, Inc. Announces Pricing of Public Offering of Common Stock
  Business Wire
- AppLovin Files Registration Statement for Proposed Initial Public Offering
  Business Wire
Business Wire
Karuna Therapeutics Announces Proposed Public Offering of Common Stock
Karuna Therapeutics, Inc. (NASDAQ: KRTX) ("Karuna"), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced that it has commenced an underwritten public offering of $200.0 million of its common stock. Karuna also intends to grant the underwriters a 30-day option to purchase an additional $30.0 million of its common stock offered in the public offering. All the shares in the proposed offering are to be sold by Karuna.
- Nurix Therapeutics Announces Launch of Proposed Public Offering of Common Stock
  GlobeNewswire
- RADA Announces Proposed Public Offering of Ordinary Shares
  GlobeNewswire
Business Wire
Karuna Therapeutics Reports Fourth Quarter and Year End 2020 Financial Results and Provides General Business Update
Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced financial results for the fourth quarter and year ended 2020 and provided a general business update.